Seelos Therapeutics Delisted From Nasdaq, Will Transition To OTC Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 15 2024
0mins
Source: Benzinga
Delisting from Nasdaq: Seelos Therapeutics has received a notice from the Nasdaq Hearings Panel to delist its common stock due to failure to meet minimum stockholder equity requirements, with trading suspended starting October 16, 2024.
PTSD Clinical Trial: The company recently signed an agreement for a clinical trial with the Department of Defense to evaluate its compound SLS-002 for PTSD in military members and veterans.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
